Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: X-ray Vision who wrote (513)	4/25/1999 11:06:00 PM
From: DanZ	Read Replies (1) \| Respond to of 5582

X-ray Vision, The clinical study for Zicam has been submitted to the NEJM. Several people told me this and I verified it with the company. This is not a rumor and it will be significant if and when it is published. The company requested a fast-track review, meaning that a decision should be made by the NEJM within two to four weeks. The amount of publicity that Zicam would receive if the NEJM publishes the clinical study would cost a fortune if GumTech had to pay for it. Sales of Quigley's Cold-Eeze increased from $1 million to $70 million in the year after their study was published by The Annals of Internal Medicine. If investors think history will repeat itself, GUMM should make a big move if the study is published. Dan